) reported second-quarter 2014 adjusted earnings per share of
$1.49, up 4.2% year over year and a penny ahead of the Zacks
Consensus Estimate. After including certain one-time items, the
company reported earnings of $1.03 a share, an increase of 15.7%
year over year.
In the second quarter, revenues stood at $1.18 billion, up 1.2% (up
0.9% at constant exchange rate or CER) year over year. However, the
top line missed the Zacks Consensus Estimate of $1.20 billion.
Revenues generated in the Americas were $640 million (down 3% year
over year at CER). The same in Europe grossed $335 million (up 5%
at CER) while in Asia-Pacific the figure was $208 million (up 7%).
Zimmer's biggest segment - Reconstructive Implant recorded revenues
of $890 million, up 2% year over year at CER. This was due to a 7%
increase in Asia Pacific and 5% sales growth in Europe. Revenues in
Americas remain at $473 million, unchanged year over year.
Revenues derived from Knees (within Reconstructive) were up 3% year
over year at CER to $498 million, while Hips recorded flat sales of
$341 million compared with the prior-year quarter. Revenues from
Extremities increased 5% year over year to $51 million.
Among the other segments at Zimmer, spine recorded a decline of 4%
at CER to $52 million whereas trauma increased 6% to $79 million in
the reported quarter. Dental and Surgical and other group, both
disappointed with decline of 1% and 10% to $61 million and $101
Zimmer's gross margin contracted 50 basis points (bps) to 71.8% in
the second quarter. Selling, general and administrative expenses
edged down 0.4% to $455.8 million while research and development
expenses were down 12.4% to $48.1 million. As a result, adjusted
operating margin expanded 76 bps to 29.2%.
Zimmer exited the quarter with cash and cash equivalents and
short-term investments of $1,698.0 million compared with $1,807.6
million as of 2013. Long-term debt increased marginally to $1.69
billion compared with $1.67 billion at the end of 2013.
Year-to-date operating cash flow was $442.9 million compared to
$370.2 million in the year-ago period. The company also paid $36.9
million dividend and declared dividends of $22.0 per share during
the quarter, an increase of 10% year over year.
2014 Outlook Lowered
Zimmer lowered its full-year 2014 revenue guidance to the range of
2.0% and 3.0% at CER from earlier range of 3.0% to 5.0%.The
currency movement is expected to lower revenues by 0.5%, which in
turn would lead to 1.5% to 2.5% revenue growth on a reported basis
(2.5% to 4.5% expected earlier).The current Zacks Consensus
Estimate for revenues remains at $4.77 billion.
The company also lowered the upper end of its 2014 adjusted
earnings guidance to the range of $6.00 to $6.10 from earlier range
of $6.00 to $6.20. This updated guidance takes into consideration
expected charges for inventory and manufacturing related expenses,
quality and operational excellence initiatives, certain claims,
special items and additional expenses related to the impending
acquisition of Biomet. The current Zacks Consensus Estimate of
$6.12 remains within the guided range.
Biomet Acquisition Update
During the first quarter earnings call, this leading player in
musculoskeletal space also disclosed that it has entered into a
definitive agreement to acquire Biomet, Inc. - provider of surgical
and non-surgical products used primarily by orthopedic surgeons and
other musculoskeletal medical specialists, for a transaction value
of $13.35 billion.
According to Zimmer, the successful completion of this acquisition,
which is expected in the first quarter of 2015, will be beneficial
for healthcare investors as the merged entity will successfully
advance innovation and help create a more diversified and
predictable revenue mix consistent with the comprehensive
The company believes this impending acquisition will be perfectly
in line with its strategic framework that focuses on growth,
operational excellence and prudent capital allocation.
Moreover, Zimmer expects enormous financial benefits from this
takeover. According to the company, upon completion, the
transaction is expected to be accretive to Zimmer's adjusted
earnings per share in double digits in the first year. Moreover, by
the third year, the net annual synergies should reach approximately
$270 million with roughly $135 million anticipated in the first
The combined entity will also likely generate operating cash
flow of more than 1.5 times Zimmer's stand-alone estimates.
Accordingly, with strong cash flow, Zimmer is expected to maintain
a stable dividend of 15% to 20% of net income following the closure
of the transaction.
Zimmer reported a mixed second quarter with a bottom-line beat and
a top-line miss. Barring Americas, we are encouraged by the overall
sales growth in the other geographies which acted as a major upside
for the company.
We believe, with the grand $13.35 billion acquisition of Biomet,
Zimmer will be able to create a market leader in the $45 billion
musculoskeletal industry thereby improving the merged entity's
position in the competitive niche. We are impressed with the
company's strong strategic and financial goals which the combined
entity expects to reach after closing of the deal.
However, the intense competition in the orthopedic market and
pricing pressure remain areas of concern. Besides, macroeconomic
uncertainties, pricing pressure and unfavorable currency adversely
impacted sales during the reported quarter.
Currently, Zimmer carries a Zacks Rank #3 (Hold). Some of the
better-placed medical products stocks are
Mead Johnson Nutrition Company
), all carrying a Zacks Rank #2 (Buy).
Want the latest recommendations from Zacks Investment Research?
Today, you can download 7 Best Stocks for the Next 30 Days.
Click to get this free report
ZIMMER HOLDINGS (ZMH): Free Stock Analysis
CAREFUSION CORP (CFN): Free Stock Analysis
ALERE INC (ALR): Free Stock Analysis Report
MEAD JOHNSON NU (MJN): Free Stock Analysis
To read this article on Zacks.com click here.